OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Harrison on Choosing Frontline Treatment for RCC

December 1st 2017

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).

Dr. Friedlander on Checkpoint Inhibitors in the Second-Line Setting of Bladder Cancer

November 30th 2017

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.

Dr. Sabbatini on Novel Approaches With IP Therapy For Ovarian Cancer

November 30th 2017

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.

Dr. Atkinson on Novel Combinations in Melanoma

November 30th 2017

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses novel combinations for the treatment of patients with melanoma.

Dr. Luke on the Clinical Trial Landscape for Melanoma

November 29th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the clinical trial landscape for melanoma

Dr. Yardley on BOLERO-2 Results for HR+ Breast Cancer

November 29th 2017

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

Dr. Kim on the Importance of Biomarker Testing for Lung Cancer

November 29th 2017

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.

Dr. Bendell on the Treatment of Microsatellite Stable Patients With CRC

November 28th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable.

Dr. Pusztai on Challenges With Neoadjuvant HER2 Therapy

November 28th 2017

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Dr. Young on the Challenges of Using Anticoagulants in Children With Cancer

November 28th 2017

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.

Dr. Haldorsen Discusses the Challenges With Imaging in Endometrial Cancer

November 28th 2017

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the challenges with imaging in endometrial cancer.

Dr. Hendifar Discusses a 92-Gene Assay of NETs

November 28th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses a 92-gene assay of patients with neuroendocrine tumors (NETs).

Dr. Gainor Discusses the Future of EGFR+ NSCLC

November 28th 2017

Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer.

Dr. Dottino on Targeted Therapies in Ovarian Cancer

November 28th 2017

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses targeted therapies for patients with ovarian cancer.

Dr. O'Connor on the Role of Obinutuzumab in Follicular Lymphoma

November 28th 2017

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the role of obinutuzumab (Gazyva) in the treatment of patients with follicular lymphoma.

Dr. Califano on the Role of Multidisciplinary Care for Head and Neck Cancer

November 28th 2017

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the role of multidisciplinary care for patients with head and neck cancer.

Dr. Holzbeierlein on the Management of Bladder Cancer Guidelines

November 23rd 2017

Jeffrey M. Holzbeierlein, MD, professor, director of Urologic Oncology, Department of Urology, University of Kansas Medical Center, discusses the management guidelines for patients with bladder cancer.

Dr. Shah on the Importance of CAR T-Cell Therapy for ALL

November 23rd 2017

Bijal D. Shah, MD, medical oncology, Moffit Cancer Center, discusses the importance of chimeric antigen receptor (CAR) T-cell therapy for patients with acute lymphoblastic leukemia (ALL).

Dr. Pant Discusses the Current Treatment Landscape of CRC

November 22nd 2017

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape of colorectal cancer.

Dr. Rai Discusses CLL in Older Populations

November 22nd 2017

Kanti R. Rai, MD, discusses older populations with chronic lymphocytic leukemia.